New monoclonal antibody sharply reduces risk of severe COVID outcomesThe monoclonal antibody sotrovimab reduced the risk of hospitalization or death from COVID-19 by 85% compared with placebo, according to an interim analysis of a phase 3 clinical trial published yesterday in the New England Journal of Medicine.In the double-blind, multicenter trial, non-hospitalized patients with symptomatic COVID-19 and at least one risk factor for disease progression were randomly assigned to receive either 500 milligrams of sotrovimab, a pan-sarbecovirus monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology, or placebo.